1. Home
  2. Vol 26, No 8 (2022)
  3. Ali

Polycystic ovary syndrome and metabolic disorders: A review of the literature

Aus Tariq Ali(1), Osamah Al-ani(2), Faisal Al-ani(3), Franco Guidozzi(4),


(1) Faculty of Health Sciences, University of the Witwatersrand, Parktown, 2193, Johannesburg, South Africa
(2) Park lane Hospital, Parktown 2193, Johannesburg, South Africa
(3) Park lane Hospital, Parktown 2193, Johannesburg, South Africa
(4) Faculty of Medicine, Odessa National Medical University, Odessa 65000, Oblast, Ukraine
Corresponding Author

Abstract


Polycystic ovarian syndrome (PCOS) is one of the most common female endocrinopathies and is a leading cause of infertility. The syndrome derives its name from the pathological appearance of the ovary in women with menstrual irregularities and hyperandrogenism. Its symptoms appear as early as adolescence in the form of amenorrhea, hirsutism and obesity. The majority of patients are overweight, obese or of normal weight, but metabolically obese. The prevalence of PCOS is on the increase and is associated with a significantly higher risk of various metabolic disorders including cardiovascular disease (CVD), Type2 diabetes (T2DM), gestational diabetes, hypercholesterolemia and different types of cancer, including endometrial and possibly ovarian cancer, especially if associated with hyperinsulinaemia. In contrast, in women with PCOS who have normal insulin levels, it is likely that genetics, inflammation, oxidative stress and possible interaction with environmental factors are present that link these women to metabolic disorders. The mechanism of PCOS is not well understood and this review aims to provide a detailed description of the mechanism underlying the development of PCOS and associated metabolic disorders with a full description of all possible scenarios associating PCOS to metabolic disorders, as well as an epidemiological overview regarding the relationship between these metabolic disorders and PCOS. (Afr J Reprod Health 2022; 26[8]: 89-99).

References


. Stein IF and Leventhal Ml. Amenorrhea associated with

bilateral polycystic ovaries. Am J Obstet Gynecol

; 29: 181-1.

Deswal R, Narwal V, Dang A and Pundir CS. The

prevalence of polycystic ovary syndrome: A brief

systematic review. J Hum Reprod Sci. 2020;

(4):261-271.

Kauffman RP, Baker VM, Dimarino P, Gimpel T and

Castracane VD. Polycystic ovarian syndrome and

insulin resistance in white and Mexican American

women: a comparison of two distinct populations.

Am J Obstet Gynecol 2002; 187(5):1362-9.

Ali AT. Polycystic ovary syndrome and metabolic

syndrome. Ceska Gynekol. 2015;80(4):279-89.

Ali AT, Ferris WF, Naran NH and Crowther NJ. Insulin

resistance in the control of body fat distribution:

a new hypothesis. Horm and Metab Res, 2011,

: 77-0.

Legro RS, Kunselman AR, Dodson WC and Dunaif A.

Prevalence and predictors of risk for type 2 diabetes

mellitus and impaired glucose tolerance in

polycystic ovary syndrome: a prospective,

controlled study in 254 affected women. J Clin

Endocrinol Metab 1999; 84: 165-9.

Cheung LP, Ma RC, Lam PM, Lok LH, Haines CJ, So WY,

Tong PCY, Cockrm CS, Chow CC and Goggins

WB. Cardiovascular risks and metabolic syndrome

in Hong Kong Chinese women with polycystic

ovary syndrome. Hum Reprod 2008; 23(6): 1431-8.

Elting MW, Korsen TJ, Bezemer PD and Schoemaker J.

Prevalence of diabetes mellitus, hypertension and

cardiac complaints in a follow-up study of a Dutch

PCOS population. Hum Reprod 2001; 16: 556-0.

Moran LJ, Misso ML, Wild RA and Norman RJ. Impaired

glucose tolerance, type2 diabetes and metabolic

syndrome in polycystic ovary syndrome: a

systematic review and meta-analysis. Hum Reprod

Update 2010; 16: 347-3.

Hillman JK, Johnson LN, Limaye M, Feldman RA,

Sammel M and Dokras A. Black women with

polycystic ovary syndrome (PCOS) have increased

risk for metabolic syndrome and cardiovascular

disease compared with white women with PCOS.

Fertil Steril 2014; 101(2): 530-5.

Schindler AE. Progestogen deficiency and endometrial

cancer risk. Maturitas 2009; 62: 334-7.

Haoula Z, Salman M and Atiomo W. Evaluating the

association between endometrial cancer and

polycystic ovary syndrome. Hum Reprod 2012;

:1327-1.

Dumesic DA and Lobo RA. Cancer risk and PCOS.

Steroids 2013; 78: 782-5.

Valkenburg O, Steegers-Theunissen RP, Smedts HP,

Dallinga-Thie GM, Fauser BC, Westerveld EH and

Laven JS. A more atherogenic serum lipoprotein

profile is present in women with polycystic ovary

syndrome: a case-control study. J Clin Endocrinol

Metab 2008; 93: 470-6.

Wild S, Pierpoint T, Jacobs H and McKeigue P. Long-term

consequences of polycystic ovary syndrome: results

of a 31 year follow-up study. Hum Fertil 2000;

(2):101-5.

Schmidt J, Landin-Wilhelmsen K, Brännström M and

Dahlgren Eva. Cardiovascular Disease and Risk

Factors in PCOS Women of Postmenopausal Age: A

Ali et al. Polycystic ovary syndrome and metabolic disorders

African Journal of Reproductive Health August 2022; 26 (8): 98

-Year Controlled Follow-Up Study. J Clin

Endocrinol Metab 2011; 96(12): 3794-3.

Marx TL and Mehta AE. Polycystic ovary syndrome:

pathogenesis and treatment over the short and long

term. Cleve Clin J Med 2003; 70 (1): 31-5.

Pache TD, Chadha S, Goorens LJG, Hop WCJ, Jaarsm

KW, Dommerholtn HBR and Fauser BC. Ovarian

morphology in long term androgen-treated female to

male transsexuals. A human model for the study of

polycystic ovarian syndrome? Histopathology 1991;

:445–2.

Levens ED, Whitcomb BW, Csokmay JM and Nieman LK.

Selective venous sampling for androgen-producing

ovarian pathology. Clin Endocrinol 2009; 70(4):

-4.

Vendola KA, Zhou J, Adesanya OO, Weil SJ and Bondy

CA. Androgens stimulate early stages of follicular

growth in the primate ovary. J Clin Invest 1998; 101:

-9.

Padmanabhan V and Veiga-Lopez A. Sheep models of

polycystic ovary syndrome phenotype. Mol Cell

Endocrinol 2013; 373:8-0.

Thathapudi S, Kodati V, Erukkambattu J, Katragadda A,

Addepally U and Hasan Q. Tumor necrosis factoralpha and polycystic ovarian syndrome: a clinical,

biochemical and molecular genetics study. Genet

Test Mol Biomarkers 2014; 18(9): 605-9.

Crave JC, Fimbel S, Lejeune H, Cugnardey N, Déchaud H

and Pugeat M. Effects of diet and metformin

administration on sex hormone-binding globulin,

androgens, and insulin in hirsute and obese women.

J Clin Endocrinol Metab 1995; 80(7): 2057-2.

Huber-Buchholz MM, Carey DG and Norman RJ.

Restoration of reproductive potential by lifestyle

modification in obese polycystic ovary syndrome:

role of insulin sensitivity and luteinizing hormone. J

Clin Endocrinol Metab1999; 84: 1470-4.

Clark AM, Thornley B, Tomlinson L, Galletley C and

Norman RJ. Weight loss in obese infertile women

results in improvement in reproductive outcome for

all forms of fertility treatment. Hum Reprod 1998;

(6): 502-5.

Holte J, Bergh T, Berne C, Wide L and Lithell H. Restored

insulin sensitivity but persistently increased early

insulin secretion after weight loss in obese women

with polycystic ovary syndrome. J Clin Endocrinol

Metab1995; 80:2586‐3.

da Silva Bouzas IC, Cader SA, Leão L, Kuschnir MC and

Braga C. Menstrual cycle alterations during

adolescence: early expression of metabolic

syndrome and polycystic ovary syndrome. J Pediatr

Adolesc Gynecol 2014; 27(6):335-1.

Calle EE and Kaaks R. Overweight, obesity and cancer:

epidemiological evidence and proposed

mechanisms. Nat Rev Cancer 2004; 4(8): 579-1.

Brettenthaler N, De Geyter C, Huber PR and Keller U.

Effect of the insulin sensitizer pioglitazone on

insulin resistance, hyperandrogenism, and ovulatory

dysfunction in women with polycystic ovary

syndrome. J Clin Endocrinol Metab 2004; 89(8):

-0.

Zhou R, Bruns CM, Bird IM, Kemnitz JW, Goodfriend TL,

Dumesic DA and Abbott DH. Pioglitazone

improves insulin action and normalizes menstrual

cycles in a majority of prenatally androgenized

female rhesus monkeys. Reprod Toxicol 2007;

(3): 438-8.

De Leo V, la Marca A, Morgante G, Ciotta L, Mencaglia

L, Cianci A and Petraglia F. Clomiphene citrate

increases insulin-like growth factor bindingprotein1 and reduces insulin-like growth factor-I without

correcting insulin resistance associated with

polycystic ovary syndrome. Human Reprod 2000;

: 2302-5.

Stadtmauer LA, Toma SK, Riehl RM and Talbert LM.

Metformin treatment of patients with polycystic

ovary syndrome undergoing in vitro fertilization

improves outcomes and is associated with

modulation of the insulin-like growth factors. Fertil

Steril 2001; 75(3): 505-9.

Kahsar-Miller MD, Nixon C, Boots LR, Go RC and Azziz

R. Prevalence of polycystic ovary syndrome (PCOS)

in first-degree relatives of patients with PCOS. Fertil

Steril 2001; 75(1): 53-8.

Yildiz BO, Yarali H, Oguz H and Bayraktar M. Glucose

intolerance, insulin resistance, and

hyperandrogenemia in first degree relatives of

women with polycystic ovary syndrome. J Clin

Endocrinol Metab 2003; 88(5): 2031-6.

Raja-Khan N, Urbanek M, Rodgers RJ and Legro RS. The

role of TGF-β in polycystic ovary syndrome. Reprod

Sci. 2014; 21(1):20-1.

Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK

and Imperial J. Prevalence of impaired glucose

tolerance and diabetes in women with polycystic

ovary syndrome. Diabetes Care 1999; 22(1): 141-6.

Grundy SM, Hansen B and Smith SC Jr. Clinical

management of metabolic syndrome: report of the

American Heart Association/National Heart, Lung,

and Blood Institute/American Diabetes Association

conference on scientific issues related to

management. Circulation 2004; 109: 551-6.

Van Gaal LF, Mertens IL and De Block CE. Mechanism

linking obesity with cardiovascular disease. Nature

; 444: 875-0.

Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C,

Manzoli L and Pasquali R. Polycystic ovary

syndrome is a risk factor for type 2 diabetes, Results

from a long-term prospective study. Diabetes 2012;

: 2369-4.

Conway G, Argawal D, Betteridge and Jacobs H. Risk

Factors for coronary artery disease in lean and obese

women with polycystic ovary syndrome. Clin

Endocrinol 1992; 37: 119-5.

Bass KM, Newschaffer CJ, Klag MJ and Bush TL. Plasma

lipoprotein levels as predictors of cardiovascular

death in women. Arch Intern Med 1993; 153(19):

-6.

Ali AT and Guidozzi F. Midlife women’s health

consequences associated with polycystic ovary

syndrome. Climacteric 2020; 23(2): 116-122.

Boorsma W, Snijder MB, Nijpels G, Guidone C, Favuzzi

AM, Mingrone G, Kostense PJ, Heine RJ and

Dekker JM. Body composition, insulin sensitivity,

Ali et al. Polycystic ovary syndrome and metabolic disorders

African Journal of Reproductive Health August 2022; 26 (8): 99

and cardiovascular disease profile in healthy

Europeans. Obesity (Silver Spring). 2008;

(12):2696-2701.

Desai V, Prasad NR, Manohar SM, Sachan A, Narasimha

SR and Bitla AR. Oxidative stress in non-obese

women with polycystic ovarian syndrome. J Clin

Diagn Res. 2014; 8(7):CC01-3.

Csányi G and Miller FJ Jr. Oxidative stress in

cardiovascular disease. Int J Mol Sci. 2014;

(4):6002-8.

Zuo T, Zhu M and Xu W. Roles of Oxidative Stress in

Polycystic Ovary Syndrome and Cancers. Oxid Med

Cell Longev. 2016; 2016:8589318.

Peppa M, Koliaki C, Papaefstathiou A, Garofios E,

Katsilambros N, Raptis SA, Hadjidakis DI and

Dimitriadis GD. Body composition determinants of

metabolic phenotypes of obesity in nonobese and

obese postmenopausal women. Obesity (Silver

Spring). 2013;21(9):1807-4.

Ruderman N, Chisholm D, X Pi-Sunyer and Schneider S.

The metabolically obese, normal-weight individual

revisited. Diabetes 1998; 47:5699-3.

Klaunig JE, Wang Z, Pu X and Zhou S. Oxidative stress

and oxidative damage in chemical carcinogenesis.

Toxicol Appl Pharmacol. 2011; 254 (2):86-9.

Ali AT. Reproductive factors and the risk of endometrial

cancer. Int J Gynecol Cancer 2014; 24(3): 384-3


Full Text: PDF

Article Metrics

Abstract View : 1160 times
PDF Download : 390 times

Refbacks

  • There are currently no refbacks.